20 results about "Narcolepsy" patented technology

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The present invention aims to provide a novel compound which has an OX2R agonist activity.The present invention relates to a cyclopentane compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof has an agonist activity on OX2R and is useful as an agent for the treatment of sleep disorders involving OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to physical diseases, hypersomnia due to psychiatric disorders, hypersomnia due to drugs or substances, circadian rhythm sleep-wake disorder, insufficient sleep syndrome and long sleep) or the like.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The present invention relates to a medicament for the treatment or prevention of a disease related to the orexin receptor, especially the orexin receptor type 2, comprising a novel compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient; more specifically, the present invention relates to a medicament for the treatment or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present application is directed, in general, to tolerizing immune mediated particles comprising narcolepsy with cataplexy (NT1) antigens for use in treating NT1.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The invention discloses a deep learning-based narcolepsy automatic identification method, and relates to the technical field of narcolepsy identification. The method comprises the following steps: reading, preprocessing and segmenting EEG / ECG sleep data of multiple subjects; an electroencephalogram feature extraction module based on a Kollogov-Arnod network (KAN) is adopted; an electrocardio feature extraction module based on ResNet18 transfer learning is adopted; feature integration is realized through a feature fusion module combining an external attention mechanism and a gating fusion scheme; and inputting the fused sleep heart-brain electrical features into a classifier for classification. Through innovative application of the deep learning technology, the defects of an existing method in feature extraction, fusion and classification are overcome, the efficiency and accuracy of sleep staging and narcolepsy recognition are remarkably improved, and the method has important clinical application value.

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

To provide a heterocyclic compound having orexin type 2 receptor agonist activity. [Solution] Formula (I): JPEG2026086676000082.jpg3177 [In the formula, each symbol is as described in the specification.] The compound represented by or its salts has orexin type 2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for narcolepsy.

The present invention provides heterocyclic compounds having orexin type 2 receptor agonist activity. Formula (I): JPEG0007821946000071.jpg65163 (wherein each symbol is as defined in the specification.) The compound represented by the formula (I) or a salt thereof has orexin type 2 receptor agonist activity and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention relates to a novel indazole derivative, and a use thereof, wherein the indazole derivative has excellent TRIB2 or YAP inhibitory activity, and can be effectively used as a pharmaceutical composition for preventing or treating cancer, narcolepsy, and fasciitis.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.

The present invention relates to a cycloalkene derivative having an orexin 2 receptor (OX2R) agonistic activity. Specifically, the present invention relates to a compound as represented by general formula (I), a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable salts of said stereoisomer and tautomer. The present invention further relates to a pharmaceutical composition containing the compound, a preparation method therefor, and the use thereof as an orexin 2 receptor (OX2R) agonist in the prevention or treatment of diseases associated with the orexin 2 receptor (OX2R) agonistic effect, such as narcolepsy, hypersomnia, sleep apnea, post-anesthesia recovery or respiratory inhibition amelioration, wherein each substituent in the general formula (I) is the same as that defined in the description.

Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.